ArticleInternational journal of cancer2010
MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.
Article in International journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- APR-246 induces early cell death by ferroptosis in acute myeloid leukemia.Haematologica · 2022Article
- MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.Scientific reports · 2021Article
- Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies.Cells · 2021Review
- Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.Leukemia · 2018Article
- Paired box 8 suppresses tumor angiogenesis and metastasis in gastric cancer through repression of FOXM1 via induction of microRNA-612.Journal of experimental & clinical cancer research : CR · 2018Article
- PRIMA-1 and PRIMA-1Cancers · 2017Review
- Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.BMC cancer · 2016Article
- PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer.British journal of cancer · 2014Article
- The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment.BioMed research international · 2014Review
- Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer.Frontiers in oncology · 2014Article
- Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Translational research : the journal of laboratory and clinical medicine · 2013Article
- miR-Explore: Predicting MicroRNA Precursors by Class Grouping and Secondary Structure Positional Alignment.Bioinformatics and biology insights · 2013Article
- Non-coding RNAs as theranostics in human cancers.Journal of cellular biochemistry · 2012Review
- MicroRNAs - Important Molecules in Lung Cancer Research.Frontiers in genetics · 2011Article
- Pharmacological activation of p53 in cancer cells.Current pharmaceutical design · 2011Review
- [MicroRNAs as therapeutic targets for lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Restoration of p53 function in tumor cells would be an attractive strategy for lung cancer therapy because p53 mutations are found in more than 50% of lung cancers. The small molecule PRIMA-1 has been shown to restore the tumor suppression function of p53 and to induce apoptosis in human tumor cells. The mechanism of apoptosis induced by PRIMA-1 remains unclear. We investigated the effects of PRIMA-1 in apoptosis with Western immunoblot analysis, TaqMan microRNA real-time PCR, cell viability analysis and flow cytometry using human lung cancer cell lines containing mutant (H211 and H1155), wild-type (A549) or null (H1299) p53. PRIMA-1 induced massive apoptosis in the H211 and H1155 cells, but was less toxic to the A549 and H1299 cells. Western immunoblot analysis showed cleavage of PARP in H211 and H1155 cells but not in A549 and H1299 cells following treatment with PRIMA-1. In addition, p53 protein was also phosphorylated in H211 and H1155 cells. TaqMan microRNA assay showed that the expression of microRNA-34a was increased in the H211 and H1155 cells posttreatment. Knockdown microRNA-34a decreased the rate of apoptosis caused by PRIMA-1. The above results suggest that microRNA-34a is one of the important components of PRIMA-1-induced apoptotic network in the cancer cells harboring mutant p53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.